191 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
launches and Beyfortus late-season deliveries were partially offset by the impact of generic competition on Aubagio as well as lower sales of Lantus … of comparison for Vaccines due to COVID-19 vaccine sales recorded in Q1 2023 which more than offset the strong performance of Dupixent.
Rest of World sales
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
or deduction, we may be required to pay you additional amounts to offset such withholding except as provided above in “Description of the Debt Securities … short-term capital gain or ordinary income. The ability of individual U.S. holders to offset capital losses against ordinary income is limited.
Despite
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
decline moderated (down 2.4%), reflecting accelerated growth of core assets (up 6.3%), offset by lower sales of Lantus and non-core asset divestment … partially offset by the impact of generic competition on Aubagio and Mozobil as well as lower sales of influenza vaccines and Lantus.
In Europe, fourth
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
of our growth drivers more than offset the expected impact from generic competition on Aubagio® in U.S. and lower sales from mature products across … % to €5,648 million. The strong performance of Dupixent® and Nexviazyme® as well as the launches of Beyfortus® and ALTUVIIIO® were partially offset
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
million. The strong performance of Specialty Care in the U.S. driven by Dupixent® and Nexviazyme® was more than offset by the impact of generic … of 2023, Biopharma sales increased by 4.1% to €17,467 million reflecting the strong performance of Specialty Care and Vaccines, partially offset
6-K
EX-99.2
133l1j8 l4k2q6
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
xlp1t t5dicf0g
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
11-K
t3cdqq yxab
28 Jun 23
Annual report of employee stock purchases
2:32pm
6-K
EX-99.1
73ixloek0vg1bu
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
SC TO-T/A
vab13l4wjhahs9sjs
27 Apr 23
Third party tender offer statement (amended)
6:16am
SC TO-T/A
in18zlb5sy
26 Apr 23
Third party tender offer statement (amended)
6:16am
SC TO-T/A
6ucihfe44cv1
10 Apr 23
Third party tender offer statement (amended)
4:38pm
S-8
okem1r9cl pjppqa1gie
30 Mar 23
Registration of securities for employees
1:36pm
6-K
EX-99.1
bbh0arjuu zb3na7cx
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
a8ncw
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
8rebdf865r7j
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
11-K
pk764rc5
29 Jun 22
Annual report of employee stock purchases
11:48am
S-8
4eypco
18 May 22
Registration of securities for employees
3:48pm
6-K
EX-99.1
wu5401qr
16 May 22
IFRS net sales reported
1:45pm
6-K
EX-99.1
70xjn 7y3pcufzf6x
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm